Home Cart 0 Sign in  

[ CAS No. 1265917-14-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 1265917-14-3
Chemical Structure| 1265917-14-3
Structure of 1265917-14-3 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1265917-14-3 ]

Related Doc. of [ 1265917-14-3 ]

Alternatived Products of [ 1265917-14-3 ]

Product Details of [ 1265917-14-3 ]

CAS No. :1265917-14-3 MDL No. :MFCD27963345
Formula : C20H24ClN3O2 Boiling Point : -
Linear Structure Formula :- InChI Key :SHRYQZBTQDMGLZ-UHFFFAOYSA-N
M.W : 373.88 Pubchem ID :50914801
Synonyms :
E-52862 hydrochloride;S1RA (hydrochloride);P 027;E-52862;S1RA hydrochloride

Calculated chemistry of [ 1265917-14-3 ]

Physicochemical Properties

Num. heavy atoms : 26
Num. arom. heavy atoms : 15
Fraction Csp3 : 0.35
Num. rotatable bonds : 5
Num. H-bond acceptors : 4.0
Num. H-bond donors : 0.0
Molar Refractivity : 109.31
TPSA : 39.52 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : No
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : Yes
Log Kp (skin permeation) : -5.52 cm/s

Lipophilicity

Log Po/w (iLOGP) : 0.0
Log Po/w (XLOGP3) : 4.31
Log Po/w (WLOGP) : 3.47
Log Po/w (MLOGP) : 2.73
Log Po/w (SILICOS-IT) : 3.15
Consensus Log Po/w : 2.73

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -4.97
Solubility : 0.004 mg/ml ; 0.0000107 mol/l
Class : Moderately soluble
Log S (Ali) : -4.85
Solubility : 0.00524 mg/ml ; 0.000014 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -5.69
Solubility : 0.000756 mg/ml ; 0.00000202 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 2.0
Synthetic accessibility : 2.9

Safety of [ 1265917-14-3 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1265917-14-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1265917-14-3 ]

[ 1265917-14-3 ] Synthesis Path-Downstream   1~1

  • 1
  • 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine [ No CAS ]
  • [ 1265917-14-3 ]
YieldReaction ConditionsOperation in experiment
63% With hydrogenchloride In ethanol 1 Synthesis of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (compound 63) and its hydrochloride salt Compound 63 (6.39 g) was dissolved in ethanol saturated with HCl, The mixture was stirred then for some minutes and evaporated to dryness. The residue was crystallized from isopropanol. The mother liquors from the first crystallization afforded a second crystallization by concentrating. Both crystallizations taken together yielded 5.24 g (63%) of the corresponding hydrochloride salt (m.p. = 197-199°C). 1H-NMR (DMSO-d6) 6 ppm: 10,85 (bs, 1H), 7,95 (m, 4H), 7,7 (dd, J=2,2, 8,8 Hz,1H), 7,55 (m, 2H), 5,9 (s, 1H), 4,55 (m, 2H), 3,95 (m, 2H), 3,75 (m, 2H), 3,55-3,4 (m,4H), 3,2 (m, 2H), 2,35 (s, 3H).HPLC purity: 99.8%
63% With hydrogenchloride In ethanol 1 Example 1. Compound 63 (6.39 g) was dissolved in ethanol saturated with HCl, The mixture was stirred then for some minutes and evaporated to dryness. The residue was crystallized from isopropanol. The mother liquors from the first crystallization afforded a second crystallization by concentrating. Both crystallizations taken together yielded 5.24 g (63 %) of the corresponding hydrochloride salt (m.p. = 197-199°C). 1H-NMR (DMSO-d6) δ ppm: 10,85 (bs, 1 H), 7,95 (m, 4H), 7,7 (dd, J=2,2, 8,8 Hz, 1 H), 7,55 (m, 2H), 5,9 (s, 1 H), 4,55 (m, 2H), 3,95 (m, 2H), 3,75 (m, 2H), 3,55-3,4 (m, 4H), 3,2 (m, 2H), 2,35 (s, 3H).
63% With hydrogenchloride In ethanol 1 Example 1: Synthesis of 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine hydrochloride (compound 63·HCl) Example 1: Synthesis of 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine hydrochloride (compound 63·HCl)Compound 63 (6.39 g) was dissolved in ethanol saturated with HCl. The mixture was stirred then for some minutes and evaporated to dryness. The residue was crystallized from isopropanol. The mother liquors from the first crystallization afforded a second crystallization by concentrating. Both crystallizations taken together yielded 5.24 g (63 %) of the corresponding hydrochloride salt (m.p. = 197-199°C.) 1H-NMR (DMSO-d6) δ ppm: 10,85 (bs, 1H), 7,95 (m, 4H), 7,7 (dd, J=2,2, 8,8 Hz, 1 H), 7,55 (m, 2H), 5,9 (s, 1 H), 4,55 (m, 2H), 3,95 (m, 2H), 3,75 (m, 2H), 3,55-3,4 (m, 4H), 3,2 (m, 2H), 2,35 (s, 3H). HPLC purity: 99.8%
63% With hydrogenchloride In ethanol 1 Example 1 : Synthesis of 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3- yloxy]ethyl} morpholine hydrochloride (compound 63-HCI) Compound 63 Compound 63-HCI Compound 63 can be prepared as disclosed in the previous application WO2006/021462. Its hydrochloride can be obtained according the following procedure:Compound 63 (6.39 g) was dissolved in ethanol saturated with HCI. The mixture was stirred then for some minutes and evaporated to dryness. The residue was crystallized from isopropanol. The mother liquors from the first crystallization afforded a second crystallization by concentrating. Both crystallizations taken together yielded 5.24 g (63 %) of the corresponding hydrochloride salt (m.p. = 197-199°C.)1H-NMR (DMSO-de) δ ppm: 10,85 (bs, 1 H), 7,95 (m, 4H), 7,7 (dd, J=2,2, 8,8 Hz, 1 H), 7,55 (m, 2H), 5,9 (s, 1 H), 4,55 (m, 2H), 3,95 (m, 2H), 3,75 (m, 2H), 3,55-3,4 (m, 4H), 3,2 (m, 2H), 2,35 (s, 3H).HPLC purity: 99.8%
63% With hydrogenchloride In ethanol 1 Example 1. Synthesis of 4-{2-[5-Methyl-1 -(naphthalen-2-yl)-1 H-pyrazol-3- yloxy]ethyl} morpholine (compound 63) and its hydrochloride salt Compound 63 can be prepared as disclosed in the previous application WO2006/021462. Its hydrochloride can be obtained according the following procedure: Compound 63 (6.39 g) was dissolved in ethanol saturated with HCI, the mixture was stirred then for some minutes and evaporated to dryness. The residue was crystallized from isopropanol. The mother liquors from the first crystallization afforded a second crystallization by concentrating. Both crystallizations taken together yielded 5.24 g (63 %) of the corresponding hydrochloride salt (m.p. = 197-199°C.) 1H-NMR (DMSO-de) δ ppm: 10,85 (bs, 1 H), 7,95 (m, 4H), 7,7 (dd, J=2,2, 8,8 Hz, 1 H), 7,55 (m, 2H), 5,9 (s, 1 H), 4,55 (m, 2H), 3,95 (m, 2H), 3,75 (m, 2H), 3,55-3,4 (m, 4H), 3,2 (m, 2H), 2,35 (s, 3H). HPLC purity: 99.8%
63% With hydrogenchloride In ethanol 1 Example 1. Synthesis of 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine (compound 63) and its hydrochloride salt Example 1. Synthesis of 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine (compound 63) and its hydrochloride salt (0108) (0109) Compound 63 can be can be prepared as disclosed in the previous application . Its hydrochloride can be obtained according the following procedure: Compound 63 (6,39 g) was dissolved in ethanol saturated with HCl, the mixture was stirred then for some minutes and evaporated to dryness. The residue was crystallized from isopropanol. The mother liquors from the first crystallization afforded a second crystallization by concentrating. Both crystallizations taken together yielded 5,24 g (63 %) of the corresponding hydrochloride salt (m.p. = 197-199°C.) 1H-NMR (DMSO-d6) δ ppm: 10,85 (bs, 1H), 7,95 (m, 4H), 7,7 (dd, J=2,2, 8,8 Hz, 1H), 7,55 (m, 2H), 5,9 (s, 1 H), 4,55 (m, 2H), 3,95 (m, 2H), 3,75 (m, 2H), 3,55-3,4 (m, 4H), 3,2 (m, 2H), 2,35 (s, 3H). HPLC purity: 99.8%
63% With hydrogenchloride In ethanol 1 Example 1 Compound 63 can be can be prepared as disclosed in the previous application . Its hydrochloride can be obtained according the following procedure: Compound 63 (6,39 g) was dissolved in ethanol saturated with HCl, the mixture was stirred then for some minutes and evaporated to dryness. The residue was crystallized from isopropanol. The mother liquors from the first crystallization afforded a second crystallization by concentrating. Both crystallizations taken together yielded 5.24 g (63 %) of the corresponding hydrochloride salt (m.p. = 197-199 °C). 1H-NMR (DMSO-d6) δ ppm: 10,85 (bs, 1H), 7,95 (m, 4H), 7,7 (dd, J=2,2, 8,8 Hz, 1H), 7,55 (m, 2H), 5,9 (s, 1H), 4,55 (m, 2H), 3,95 (m, 2H), 3,75 (m, 2H), 3,55-3,4 (m, 4H), 3,2 (m, 2H), 2,35 (s, 3H). HPLC purity: 99.8%
63% With hydrogenchloride In ethanol; water 1 Compound 63 (6,39 g) was dissolved in ethanol saturated with HC1, the mixture was stirred then for some minutes and evaporated to dryness. The residue was crystallized from isopropanol. The mother liquors from the first crystallization afforded a secondcrystallization by concentrating. Both crystallizations taken together yielded 5.24 g (63 %) of the corresponding hydrochloride salt (m.p. = 197-199 °C).
63% With hydrogenchloride In ethanol 1 Example 1 Synthesis of 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (compound 63) and its hydrochloride salt Compound 63 (6.39 g) was dissolved in ethanol saturated with HCl, the mixture was stirred then for some minutes and evaporated to dryness. The residue was crystallized from isopropanol. The mother liquors from the first crystallization afforded a second crystallization by concentrating. Both crystallizations taken together yielded 5.24 g (63%) of the corresponding hydrochloride salt (m.p.=197-199° C.). 1H-NMR (DMSO-d6) δ ppm: 10.85 (bs, 1H), 7.95 (m, 4H), 7.7 (dd, J=2.2, 8.8 Hz, 1H), 7.55 (m, 2H), 5.9 (s, 1H), 4.55 (m, 2H), 3.95 (m, 2H), 3.75 (m, 2H), 3.55-3.4 (m, 4H), 3.2 (m, 2H), 2.35 (s, 3H).
63% With hydrogenchloride In ethanol 1 Example 1 Synthesis of 4-{2-[5-methyl-1 -(naphthalen-2-yl)- 1 H-pyrazol-3-yloxy]ethyl}morpholine (Compound61) and its Hydrochloride Salt Compound 61 can be can be prepared as disclosed in the previous application W02006/021462. Its hydrochloride can be obtained according the following procedure:Compound 61(6.39 g) was dissolved in ethanol saturated with HC1, the mixture was stirred then for some minutes and evaporated to dryness. The residue was crystallized from isopropanol. The mother liquors from the first crystallization afforded a second crystallization by concentrating. Both crystallizations taken together yielded 5.24 g (63%) of the corresponding hydrochloride salt (m.p.=197-199° C.).1H-NMR (DMSO-d5)δ ppm: 10.85 (bs, 1H), 7.95 (m,4H), 7.7 (dd, J=2.2, 8.8 Hz, 1H), 7.55 (m, 2H), 5.9 (s, 1H),4.55 (m, 2H), 3.95 (m, 2H), 3.75 (m, 2H), 3.55-3.4 (m, 4H),3.2 (m, 2H), 2.35 (s, 3H). HPLC purity: 99.8%
63% With hydrogenchloride In ethanol; water Example 1 Synthesis of 4-{2-[5-Methyl-1 -(naphthalen-2-yl)-1 H-pyrazol-3-yloxy]ethyl} morpholine (compound 61) and its hydrochloride salt Compound 61 can be prepared as disclosed in the previous application W02006/021462. Its hydrochloride can be obtained according the followingprocedure:Compound 63 (6.39 g) was dissolved in ethanol saturated with HCl, the mixture was stirred then for some minutes and evaporated to dryness. The residue was crystallized from isopropanol. The mother liquors from the first crystallization afforded a second crystallization by concentrating. Both crystallizations taken together yielded 5.24 g (63%) of the corresponding hydrochloride salt (m.p. = 197-1 99 °C).1H-NMR (DMSO-d6) 6 ppm: 10,85 (bs, 1H), 7,95 (m, 4H), 7,7 (dd, J=2,2, 8,8 Hz,1H),7,55 (m, 2H), 5,9 (s, 1H), 4,55 (m, 2H), 3,95 (m, 2H), 3,75 (m, 2H), 3,55-3,4 (m, 4H),3,2 (m, 2H), 2,35 (s, 3H).HPLC purity: 99.8%.
63% With hydrogenchloride In ethanol 1 Synthesis of 4-{2-[5-Methyl-1 -(naphthalen-2-yI)-1 H-pyrazol-3-yloxy]ethyl}morpholine (compound 63) and its hydrochloride salt Compound 63 can be prepared as disclosed in the previous application W02006/021462 (Compound 63 is example 61 in W02006/021462). Itshydrochloride can be obtained according the following procedure:Compound 63 (6.39 g) was dissolved in ethanol saturated with HCI, the mixture was stirred then for some minutes and evaporated to dryness. The residue was crystallized from isopropanol. The mother liquors from the first crystallization afforded a second crystallization by concentrating. Both crystallizations taken together yielded 5.24 g (63%) of the corresponding hydrochloride salt (m.p. = 197-1 99 °C).1H-NMR (DMSO-d6) 6 ppm: 10,85 (bs, 1H), 7,95 (m, 4H), 7,7 (dd, J=2,2, 8,8 Hz,1H),7,55 (m, 2H), 5,9 (s, 1 H), 4,55 (m, 2H), 3,95 (m, 2H), 3,75 (m, 2H), 3,55-3,4 (m, 4H),3,2 (m, 2H), 2,35 (s, 3H).HPLC purity: 99.8%.
63% With hydrogenchloride In ethanol 1 Synthesis of 4-{2-[5-Methyl-1 -(naphthalen-2-yl)-1 H-pyrazol-3-yloxy]ethyl }morpholine (compound 61) and its hydrochloride salt Compound 61 (6,39 g) was dissolved in ethanol saturated with HCI, the mixture was stirred then for some minutes and evaporated to dryness. The residue was crystallized from isopropanol. The mother liquors from the first crystallization afforded a second crystallization by concentrating. Both crystallizations taken together yielded 5.24 g (63%) of the corresponding hydrochloride salt (m.p. = 197-199 C).1H-NMR (DMSO-d6) 6 ppm: 10,85 (bs, 1H), 7,95 (m, 4H), 7,7 (dd, J=2,2, 8,8 Hz,1H),7,55 (m, 2H), 5,9 (s, 1H), 4,55 (m, 2H), 3,95 (m, 2H), 3,75 (m, 2H), 3,55-3,4 (m, 4H),3,2 (m, 2H), 2,35 (s, 3H).HPLC purity: 99.8%.
5.24 g (63%) In ethanol 1 Example 1. Compound 61 (6.39 g) was dissolved in ethanol saturated with HCl, the mixture was stirred then for some minutes and evaporated to dryness. The residue was crystallized from isopropanol. The mother liquors from the first crystallization afforded a second crystallization by concentrating. Both crystallizations taken together yielded 5.24 g (63%) of the corresponding hydrochloride salt (m.p. = 197-199 °C). 1H-NMR (DMSO-d6) δ ppm: 10.85 (bs, 1H), 7.95 (m, 4H), 7.7 (dd, J=2.2, 8.8 Hz, 1H), 7.55 (m, 2H), 5.9 (s, 1H), 4.55 (m, 2H), 3.95 (m, 2H), 3.75 (m, 2H), 3.55-3.4 (m, 4H), 3.2 (m, 2H), 2.35 (s, 3H). HPLC purity: 99.8%

Reference: [1]Current Patent Assignee: Corporacion Quimico Farmaceutica Esteve SA - WO2014/170319, 2014, A1 Location in patent: Page/Page column 19; 20
[2]Current Patent Assignee: Corporacion Quimico Farmaceutica Esteve SA - EP2792352, 2014, A1 Location in patent: Paragraph 0096-0100
[3]Current Patent Assignee: Corporacion Quimico Farmaceutica Esteve SA - EP2818166, 2014, A1 Location in patent: Paragraph 0094; 0095; 0096; 0097
[4]Current Patent Assignee: Corporacion Quimico Farmaceutica Esteve SA - WO2014/207024, 2014, A1 Location in patent: Page/Page column 23
[5]Current Patent Assignee: Corporacion Quimico Farmaceutica Esteve SA - WO2015/36470, 2015, A1 Location in patent: Page/Page column 26
[6]Current Patent Assignee: Corporacion Quimico Farmaceutica Esteve SA - EP2531191, 2016, B1 Location in patent: Paragraph 0108; 0109
[7]Current Patent Assignee: Corporacion Quimico Farmaceutica Esteve SA - EP2646025, 2017, B1 Location in patent: Paragraph 0086-0087
[8]Current Patent Assignee: Corporacion Quimico Farmaceutica Esteve SA - WO2017/21002, 2017, A1 Location in patent: Page/Page column 30
[9]Current Patent Assignee: Corporacion Quimico Farmaceutica Esteve SA - US9789115, 2017, B2 Location in patent: Page/Page column 27; 28
[10]Current Patent Assignee: Corporacion Quimico Farmaceutica Esteve SA - US9789117, 2017, B2 Location in patent: Page/Page column 19
[11]Current Patent Assignee: Corporacion Quimico Farmaceutica Esteve SA - WO2017/211763, 2017, A1 Location in patent: Page/Page column 32; 33
[12]Current Patent Assignee: Corporacion Quimico Farmaceutica Esteve SA - WO2017/211765, 2017, A1 Location in patent: Page/Page column 24; 25
[13]Current Patent Assignee: Corporacion Quimico Farmaceutica Esteve SA - WO2018/11169, 2018, A1 Location in patent: Page/Page column 27
[14]Current Patent Assignee: Corporacion Quimico Farmaceutica Esteve SA - EP2524694, 2012, A1
Same Skeleton Products
Historical Records